[go: up one dir, main page]

NO972526L - Tachykininantagonister - Google Patents

Tachykininantagonister

Info

Publication number
NO972526L
NO972526L NO972526A NO972526A NO972526L NO 972526 L NO972526 L NO 972526L NO 972526 A NO972526 A NO 972526A NO 972526 A NO972526 A NO 972526A NO 972526 L NO972526 L NO 972526L
Authority
NO
Norway
Prior art keywords
phenyl
sulfur
tachykinin antagonists
indol
pyridyl
Prior art date
Application number
NO972526A
Other languages
English (en)
Other versions
NO972526D0 (no
Inventor
Soo Young Ko
Christopher Walpole
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9425085.9A external-priority patent/GB9425085D0/en
Priority claimed from GBGB9426016.3A external-priority patent/GB9426016D0/en
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO972526D0 publication Critical patent/NO972526D0/no
Publication of NO972526L publication Critical patent/NO972526L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Forbindelse med formel I, Rj -(CHj)^- I«-C-*I-----CH-C-N-----CH-C-Z-CH-Rj 1^ (b) (C) (I) hvori Rj^ er mono- eller disubstituert fenyl, n er null eller 1, Xj^ er oksygen, svovel eller =NCN, Xj og X3 er oksygen eller svovel, R2 er hydrogen eller metyl, R3 er fenyl, halogen- substituert fenyl, 2-naftyl, lH-indol-3-yl eller 1-metyl- indol-3-yl, Z er -N(CH3)- eller -CHj-, R4 er fenyl, 3,5-bis- (trifluormetyl)fenyl eller pyridyl og R5 er hydrogen, fenyl, 3,5-bis(trifluormetyl)fenyl eller pyridyl, hvorved, når X3 er svovel, er Z -N(CH3)-, og syreaddisjonssalt derav har tachykininantagonistaktivitet og er anvendbare som farma- søytiske midler, f.eks. for behandling av smerte.
NO972526A 1994-12-13 1997-06-03 Tachykininantagonister NO972526L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9425085.9A GB9425085D0 (en) 1994-12-13 1994-12-13 Organic compounds
GBGB9426016.3A GB9426016D0 (en) 1994-12-22 1994-12-22 Organic compounds
PCT/EP1995/004910 WO1996018643A1 (en) 1994-12-13 1995-12-12 Tachykinin antagonists

Publications (2)

Publication Number Publication Date
NO972526D0 NO972526D0 (no) 1997-06-03
NO972526L true NO972526L (no) 1997-06-03

Family

ID=26306161

Family Applications (1)

Application Number Title Priority Date Filing Date
NO972526A NO972526L (no) 1994-12-13 1997-06-03 Tachykininantagonister

Country Status (17)

Country Link
EP (1) EP0797583A1 (no)
JP (1) JPH10511935A (no)
AR (1) AR001332A1 (no)
AU (1) AU4343796A (no)
BR (1) BR9509997A (no)
CA (1) CA2204130A1 (no)
CO (1) CO4700289A1 (no)
CZ (1) CZ179097A3 (no)
FI (1) FI971685L (no)
HU (1) HUT77002A (no)
IL (1) IL116323A0 (no)
NO (1) NO972526L (no)
PE (1) PE38997A1 (no)
PL (1) PL320217A1 (no)
SK (1) SK74697A3 (no)
TR (1) TR199501568A2 (no)
WO (1) WO1996018643A1 (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2267153T3 (es) * 1996-10-07 2007-03-01 MERCK SHARP & DOHME LTD. Antagonistas del receptor nk-1 penetrantes del snc como agentes antidepresivos y/o antiansiedad.
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
AU759022B2 (en) 1999-02-18 2003-04-03 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
RU2309953C2 (ru) 1999-11-03 2007-11-10 Эймр Текнолоджи, Инк. Арил- и гетероарилзамещенные тетрагидроизохинолины, фармацевтическая композиция и способ лечения на их основе
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
WO2002004455A2 (en) 2000-07-11 2002-01-17 Albany Molecular Research, Inc 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
US7541357B2 (en) 2004-07-15 2009-06-02 Amr Technology, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
EP1888050B1 (en) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
JP5258561B2 (ja) 2005-07-15 2013-08-07 アルバニー モレキュラー リサーチ， インコーポレイテッド アリール置換およびヘテロアリール置換テトラヒドロベンズアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用
CN101277960A (zh) 2005-09-29 2008-10-01 默克公司 作为黑皮质素-4受体调节剂的酰化螺哌啶衍生物
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2109608B1 (en) 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
JP2010516731A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8598184B2 (en) 2008-03-03 2013-12-03 Tiger Pharmatech Protein kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
DK2429296T3 (en) 2009-05-12 2018-03-12 Albany Molecular Res Inc 7 - ([1,2,4,] TRIAZOLO [1,5, -A] PYRIDIN-6-YL) -4- (3,4-DICHLORPHENYL) -1,2,3,4- TETRAHYDROISOQUINOLINE AND USE thereof
EP2429293B1 (en) 2009-05-12 2014-10-29 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
KR20120034644A (ko) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
EP2601293B1 (en) 2010-08-02 2017-12-06 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2013537423A (ja) 2010-08-17 2013-10-03 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
CN103732592A (zh) 2011-04-21 2014-04-16 默沙东公司 胰岛素样生长因子-1受体抑制剂
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
EP2900241B1 (en) 2012-09-28 2018-08-08 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
BR112021002267A8 (pt) 2018-08-07 2023-02-07 Merck Sharp & Dohme Inibidores de prmt5
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
JPH05186498A (ja) * 1991-12-27 1993-07-27 Japan Tobacco Inc プロリン誘導体

Also Published As

Publication number Publication date
FI971685A0 (fi) 1997-04-18
CO4700289A1 (es) 1998-12-29
CA2204130A1 (en) 1996-06-20
EP0797583A1 (en) 1997-10-01
SK74697A3 (en) 1997-11-05
FI971685A7 (fi) 1997-08-13
IL116323A0 (en) 1996-03-31
FI971685L (fi) 1997-08-13
PE38997A1 (es) 1997-10-02
AU4343796A (en) 1996-07-03
NO972526D0 (no) 1997-06-03
HUT77002A (hu) 1998-03-02
PL320217A1 (en) 1997-09-15
BR9509997A (pt) 1997-12-30
WO1996018643A1 (en) 1996-06-20
AR001332A1 (es) 1997-10-22
JPH10511935A (ja) 1998-11-17
MX9703957A (es) 1997-09-30
TR199501568A2 (tr) 1996-07-21
CZ179097A3 (en) 1997-10-15

Similar Documents

Publication Publication Date Title
NO972526L (no) Tachykininantagonister
DE69133277D1 (de) Chelat-zubereitungen, die oximverbindungen enthalten
EE04310B1 (et) Bensimidasooli ühendid, neid ühendeid sisaldavad farmatseutilised kompositsioonid ja nende kasutamine
DK1105393T3 (da) Bicykliske piperidin- og piperazinforbindelser med 5-HT6-receptoraffinitet
EP1104764A4 (en) 1h-imidazopyridine derivatives
DE69929689D1 (de) Heterozyclische derivate für die behandlung von herzversagen und andere erkrankungen
ATE269312T1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren
PT641328E (pt) Derivados aza-biciclicos em ponte como antagonistas da substancia p
NO944919L (no) Fremgangsmåte for å inhibere atrofi av huden eller vagina
NO20000325L (no) Absorbentsammensetning for rensing av gasser som inneholder sure komponenter
DE60107435D1 (de) 2-adamantylethylamine und deren verwendung bei der behandlung von abnormalitäten in der glutamat transmission
ATE173256T1 (de) Azolidindion-derivate und ihre anwendung als antihyperglykämika
MX9600842A (es) Derivados de ciclos de amida.
DK0538192T3 (da) Hidtil ukendte 17beta-substituerede aza-androstan-derivater
TR200103349T2 (tr) Purin türevleri, hazırlama usulü ve bunları içeren ispençiyari bileşimleri.
NO944926L (no) Fremgangsmåter for å inhibere myeloperoksidaseaktivitet
NO961000L (no) Piperidinderivater, fremgangsmåte for fremstilling derav og medikament og preparat inneholdende slike
ATE168105T1 (de) Melamine derivate zur verwendung in der behandlung von krebs
NO971142L (no) Bis-(2-halogenetyl)aminofenylsubstituerte distamycinderivater som antitumor- og antivirale midler
JPS6440449A (en) Substituted 2-nitromethaphenylenediamine, manufacture and hair dye composition
DE69310904D1 (de) Verbrückte bis-aryl-carbinol-derivate, zusammensetzungen und ihre verwendung
NO922151L (no) Gingerol og gingerdiolderivater som hypokolesterolemiske og antiatherosklerotiske midler
ATE124686T1 (de) Phenylalkylamine und diese enthaltende fungizide.
ATE172960T1 (de) Carbamoylcarbonsäureamide
ES2105145T3 (es) Nuevos derivados de la pirrolidina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.